# A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

> **NCT06760819** · PHASE2 · RECRUITING · sponsor: **Bayer** · enrollment: 111 (estimated)

## Conditions studied

- Advanced Solid Tumors
- HER2 Mutation

## Interventions

- **DRUG:** BAY2927088

## Key facts

- **NCT ID:** NCT06760819
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-13
- **Primary completion:** 2027-02-03
- **Final completion:** 2027-10-25
- **Target enrollment:** 111 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06760819

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06760819, "A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT06760819. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*